An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Pharmacokinetics（serum concentration of ONO-7913）

Time frame: Through study completion, an average of 6 months

Pharmacokinetics（serum concentration of ONO-4538）

Time frame: Through study completion, an average of 6 months

Overall response rate (ORR)

Time frame: Through study completion, an average of 6 months

Disease control rate (DCR)

Time frame: Through study completion, an average of 6 months

Overall survival (OS)

Time frame: Through study completion, an average of 6 months

Progression-free survival (PFS)

Time frame: Through study completion, an average of 6 months

Duration of response (DOR)

Time frame: Through study completion, an average of 6 months

Time to response (TTR)

Time frame: Through study completion, an average of 6 months

Best overall response (BOR)

Time frame: Through study completion, an average of 6 months